Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes
- 1 January 2018
- journal article
- review article
- Published by Elsevier in Metabolism
- Vol. 78, 141-154
Abstract
No abstract availableKeywords
Funding Information
- NIKE
This publication has 103 references indexed in Scilit:
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week ExtensionThe Journal of Clinical Endocrinology & Metabolism, 2013
- Diabetes and Risk of CancerISRN Oncology, 2013
- Risk Factors for Obesity in Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2012
- The Frailty Syndrome: Definition and Natural HistoryClinics in Geriatric Medicine, 2011
- Postoperative Mortality in Cancer Patients With Preexisting DiabetesDiabetes Care, 2010
- Q's next: the diverse functions of glutamine in metabolism, cell biology and cancerOncogene, 2009
- Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes MellitusJAMA, 2008
- Diabetes and Risk of Non-Hodgkin's LymphomaDiabetes Care, 2008
- Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor studyBlood, 2006
- On the Origin of Cancer CellsScience, 1956